# Face Transplant Pioneer Builds Biotech, Sells It for $5.6B - Date: 2026-03-31 - Category: Biotech & Life Sciences Biogen paid $5.6B upfront—but the real bet is whether it can build a market for SYFOVRE, the first approved GA drug, when less than 10 percent of diagnosed patients currently receive any treatment. ---